SBC Medical Group Holdings Inc. (NASDAQ: SBC) implemented a dual strategy in 2025 to address competition and maintain its industry leadership by making aesthetic medicine more accessible while differentiating itself through advanced treatments and competitive pricing. These initiatives resulted in expanded clinic numbers, increased repeat business, and enhanced customer loyalty. The company's franchise locations grew to 258, representing a 15% year-over-year increase as of September 30, 2025.
Revised pricing strategies contributed to a 5% increase in average revenue per customer during the third quarter of 2025, driven by pricing optimization and attracting higher revenue-generating customers through a multi-brand approach. The company expanded its service offerings to include plastic surgery and infertility treatment, broadening its specialized medical care portfolio. International expansion efforts reached Singapore and Thailand, with plans announced for entry into the U.S. market in early 2026.
The company launched new brands including "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo, with the latter employing a hybrid dermatology model that integrates insurance-covered general dermatology with private-pay aesthetic treatments. Strategic acquisitions included MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and the related subsidiary Waqoo, whose technologies will enhance clinical offerings in areas such as AGA and orthopedics while supporting development of new treatments and skincare products.
During the third quarter, SBC Medical reported average revenue per visit increased 5% sequentially to $298, with an 8.4% increase from the first quarter of 2025. The company attributed this growth to pricing strategy overhauls, promotional efforts, and targeting more affluent customers. SBC Medical ended the quarter with a 72% repeat customer rate and operates 258 locations as of the third quarter reporting period.
The company gained increased visibility through inclusion in the Russell 3000® Index, which automatically placed it in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index, along with appropriate growth and value style indexes. The Russell indexes from global index provider FTSE Russell are widely used by investment managers and institutional investors, with approximately $18.1 trillion in assets benchmarked against the indexes globally. According to SBC Medical Group, about $10.6 trillion in assets are benchmarked against the Russell U.S. indexes in the United States alone as of June 2024.
SBC Medical announced a stock buyback program of up to $5 million, citing confidence in its growth plan and belief that the stock price undervalued the business performance, growth potential, and aesthetic medical market position. The global cosmetic surgery and procedure market was valued at $122.08 billion in 2022, with expectations for 14.7% compound annual growth from 2023 to 2030.
Beginning the year with $125 million in cash, the company made strategic acquisitions and prepared for market expansion. The acquisition of MB Career Lounge Co. Ltd. enhanced SBC Medical's management support services, while joining JUN CLINIC to its network enabled offering customized treatments at premium prices. To capitalize on cosmetic tourism, SBC actively targeted Chinese consumers visiting Japan for procedures, implementing Chinese-speaking customer service representatives, interpreters, social media outreach on Chinese platforms, and developing a dedicated app for the market.
In Singapore, SBC expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which operates multiple brands in medical aesthetics, beauty, and anti-aging within Singapore. The company entered Thailand through an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates more than 20 pharmacies and clinics in Thailand. As part of this partnership, SBC will provide management support to a new dermatological clinic BLEZ is preparing to open in Bangkok, focusing on treatments such as pigmentation and spot removal.
